Prevnar(TM): a pneumococcal conjugate vaccine for infants and young children

Brown A
Record ID 32001000048
English, French
Authors' objectives:

To summarise the available evidence on the use of the Prevnar(TM) vaccine for pneumococcal infection in infants less than two years of age.

Authors' recommendations: Streptococcus pneumoniae infections in infants and young children most commonly result in otitis media, sinusitis, pneumonia, bacteremia, and meningitis. Prevnar(TM) vaccine is an effective, but expensive, preventative measure against several forms of pneumococcal infection for infants less than two years of age. The projected cost effectiveness of a Prevnar(TM) vaccination program for healthy infants and small children is dependent upon: manufacturer's sales price; prevalence and trends of S. pneumoniae and its antibiotic resistant strains in Canadian infants and young children; vaccine efficacy; and the target populations selected for a pneumococcal conjugate vaccine program.
Authors' methods: Overview
Project Status: Completed
Year Published: 2001
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Infant
  • Pneumococcal Infections
  • Streptococcus pneumoniae
  • Vaccination
Organisation Name: Canadian Coordinating Office for Health Technology Assessment
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
Contact Email:
Copyright: Canadian Coordinating Office for Health Technology Assessment
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.